Compare MasTec Inc (MTZ) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? MasTec Inc trades at $217.29 (market cap $17.40B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.49 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| MTZ | RPRX | |
|---|---|---|
Market Cap | $17.40B | $25.27B |
Volume | 1,415,821 | 3,671,183 |
Sector | Industrials | Health |
52-Week High | $437.51 | $63.96 |
52-Week Low | $190.08 | $35.44 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $20.32B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $216.11, down 3.25% on the day, with technical indicators showing a bearish trend as the stock trades below key moving averages. The company maintains strong fundamentals with revenue growth from $14.3B in 2025 to $16.1B projected for 2026, and net income improving to $494M. Recent news highlights MTZ's positioning in infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4B backlog.
The outlook remains positive given analyst consensus of 32 Buy ratings and a $408.58 price target, representing 89% upside potential. Key risks include premium valuation metrics (P/E 34.5), weak cash flow trends, and communications segment softness. The stock's current discount to analyst targets presents a compelling opportunity if execution improves.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
